Welcome to LookChem.com Sign In|Join Free

CAS

  • or

81-81-2

Post Buying Request

81-81-2 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

81-81-2 Usage

General Description

Warfarin is a medication that belongs to the class of anticoagulants, or blood thinners. It works by inhibiting the production of certain proteins that are necessary for blood clotting, leading to a decreased risk of blood clots forming in the blood vessels. Warfarin is primarily used to treat and prevent blood clots, as well as to reduce the risk of stroke in patients with conditions such as atrial fibrillation and heart valve replacement. However, it is important to closely monitor the dosage and effects of warfarin, as it can lead to potentially dangerous bleeding if the levels in the blood become too high. Additionally, warfarin can interact with many other medications and foods, so it is crucial for patients taking this medication to follow their doctor's instructions carefully and to have regular blood tests to monitor their levels.

Check Digit Verification of cas no

The CAS Registry Mumber 81-81-2 includes 5 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 2 digits, 8 and 1 respectively; the second part has 2 digits, 8 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 81-81:
(4*8)+(3*1)+(2*8)+(1*1)=52
52 % 10 = 2
So 81-81-2 is a valid CAS Registry Number.
InChI:InChI=1/C19H16O4/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22/h2-10,15,21H,11H2,1H3

81-81-2 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Cerilliant

  • (W-003)  Warfarin solution  1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material

  • 81-81-2

  • W-003-1ML

  • 366.21CNY

  • Detail

81-81-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name warfarin

1.2 Other means of identification

Product number -
Other names Warfarin

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:81-81-2 SDS

81-81-2Synthetic route

4-hydroxy[1]benzopyran-2-one
1076-38-6

4-hydroxy[1]benzopyran-2-one

1-Phenylbut-1-en-3-one
122-57-6

1-Phenylbut-1-en-3-one

Conditions
ConditionsYield
With C23H24N2O6S*Li(1+) In tetrahydrofuran; dimethyl sulfoxide at 0℃; for 48h; Reagent/catalyst; Michael Addition;99%
With lipase In water at 50℃; for 168h; Temperature; Michael Addition; Enzymatic reaction;99.1%
With N-ethyl-N,N-diisopropylamine In water for 20h; Michael Addition; Reflux;93%
warfarin
81-81-2

warfarin

Conditions
ConditionsYield
With polystyrene-divinylbenzene support prepared cyclohexanol as porogen with immobilized 1,5,7-triazabicyclo[4.4.0]dec-5-ene at 100℃; for 96h; Reagent/catalyst; Solvent; Temperature; Time; Michael Addition; Green chemistry;96%
With L-proline In dimethyl sulfoxide at 20℃; for 15h; Michael addition;85%
With rac-Pro-OH In dimethyl sulfoxide at 20℃; for 24h;80%
With cetyltrimethylammonim bromide; 1,4-dihydropyridine-enolate In water at 20℃; for 10h; Michael addition;50%
4-hydroxy[1]benzopyran-2-one
1076-38-6

4-hydroxy[1]benzopyran-2-one

2-phenylethanol
60-12-8

2-phenylethanol

D,L-valine
516-06-3

D,L-valine

warfarin
81-81-2

warfarin

Conditions
ConditionsYield
In dimethyl sulfoxide at 20℃; for 16h;84%
4-hydroxy[1]benzopyran-2-one
1076-38-6

4-hydroxy[1]benzopyran-2-one

warfarin
81-81-2

warfarin

Conditions
ConditionsYield
With cyclopentene In chlorobenzene; toluene at 100℃; for 8h; Inert atmosphere; regioselective reaction;83%
3-(phenyl-λ3-iodanylidene)chromane-2,4-dione
86795-49-5

3-(phenyl-λ3-iodanylidene)chromane-2,4-dione

(E)-benzalacetone
1896-62-4

(E)-benzalacetone

warfarin
81-81-2

warfarin

Conditions
ConditionsYield
In acetonitrile at 80℃; for 12h;76%
(+/-)-Warfarin 4-methyl ether
38063-51-3

(+/-)-Warfarin 4-methyl ether

warfarin
81-81-2

warfarin

Conditions
ConditionsYield
With boron tribromide In dichloromethane -78 up to 0 deg C;
2-methoxywarfarin
102077-97-4

2-methoxywarfarin

warfarin
81-81-2

warfarin

Conditions
ConditionsYield
With boron tribromide In dichloromethane -78 up to 0 deg C;
4-hydroxy[1]benzopyran-2-one
1076-38-6

4-hydroxy[1]benzopyran-2-one

water
7732-18-5

water

(E)-benzalacetone
1896-62-4

(E)-benzalacetone

warfarin
81-81-2

warfarin

4-hydroxy[1]benzopyran-2-one
1076-38-6

4-hydroxy[1]benzopyran-2-one

2-Methoxypropene
116-11-0

2-Methoxypropene

benzaldehyde
100-52-7

benzaldehyde

warfarin
81-81-2

warfarin

Conditions
ConditionsYield
Stage #1: 4-hydroxy[1]benzopyran-2-one; 2-Methoxypropene; benzaldehyde With ethylenediamine diacetic acid In 1,4-dioxane at 90℃; for 4h; tandem Knoevenagel-hetero-Diels-Alder reaction;
Stage #2: With hydrogenchloride; silica gel In water; trifluoroacetic acid at 20℃;
quat-ammonium salt

quat-ammonium salt

(E)-benzalacetone
1896-62-4

(E)-benzalacetone

warfarin
81-81-2

warfarin

Conditions
ConditionsYield
In water
benzaldehyde
100-52-7

benzaldehyde

warfarin
81-81-2

warfarin

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 1-n-butyl-3-methylimidazolim bromide; bovine serum albumin; tetrabutylammomium bromide / 4 h / 60 °C / Inert atmosphere; Enzymatic reaction
2: 48 h
View Scheme
Multi-step reaction with 2 steps
1: sodium hydroxide / water / Microwave irradiation
2: N-ethyl-N,N-diisopropylamine / water / 20 h / Reflux
View Scheme
Multi-step reaction with 2 steps
1: Fe3O4(at)L-proline/Pd2 NCs / 24 h / 70 °C / Sealed tube
2: water / 12 h / 100 °C
View Scheme
warfarin
81-81-2

warfarin

(1R,2S,5R)-menthyl chloroformate
14602-86-9

(1R,2S,5R)-menthyl chloroformate

Carbonic acid (1R,2S,5R)-2-isopropyl-5-methyl-cyclohexyl ester 2-oxo-3-(3-oxo-1-phenyl-butyl)-2H-chromen-4-yl ester

Carbonic acid (1R,2S,5R)-2-isopropyl-5-methyl-cyclohexyl ester 2-oxo-3-(3-oxo-1-phenyl-butyl)-2H-chromen-4-yl ester

Conditions
ConditionsYield
With TEA In 1,2-dichloro-ethane for 0.5h; Ambient temperature;100%
warfarin
81-81-2

warfarin

N-methoxylamine hydrochloride
593-56-6

N-methoxylamine hydrochloride

4-hydroxy-3-(3-(methoxyimino)-1-phenylbutyl)-2H-1-benzopyran-2-one
1103877-12-8

4-hydroxy-3-(3-(methoxyimino)-1-phenylbutyl)-2H-1-benzopyran-2-one

Conditions
ConditionsYield
With pyridine In methanol at 20℃; for 18h;99%
warfarin
81-81-2

warfarin

A

dehydrowarfarin
67588-18-5

dehydrowarfarin

B

C18H12O3

C18H12O3

Conditions
ConditionsYield
With copper(l) iodide In pyridine at 55 - 60℃; for 5h; air;A 98%
B n/a
warfarin
81-81-2

warfarin

Methylenetriphenylphosphorane
19493-09-5

Methylenetriphenylphosphorane

4-hydroxy-3-(3-methyl-1-phenyl-3-butenyl)-2H-1-benzopyran-2-one
92824-18-5

4-hydroxy-3-(3-methyl-1-phenyl-3-butenyl)-2H-1-benzopyran-2-one

Conditions
ConditionsYield
In tetrahydrofuran; dimethyl sulfoxide95%
In tetrahydrofuran; dimethyl sulfoxide65%
warfarin
81-81-2

warfarin

3-nitro-benzaldehyde
99-61-6

3-nitro-benzaldehyde

4-hydroxy-3-[5-(3-nitro-phenyl)-3-oxo-1-phenyl-pent-4-enyl]-chromen-2-one
1189759-41-8

4-hydroxy-3-[5-(3-nitro-phenyl)-3-oxo-1-phenyl-pent-4-enyl]-chromen-2-one

Conditions
ConditionsYield
With sodium hydroxide In water at 20℃;95%
warfarin
81-81-2

warfarin

4-chlorobenzaldehyde
104-88-1

4-chlorobenzaldehyde

4-hydroxy-3-[5-(4-chloro-phenyl)-3-oxo-1-phenyl-pent-4-enyl]-chromen-2-one
1189759-36-1

4-hydroxy-3-[5-(4-chloro-phenyl)-3-oxo-1-phenyl-pent-4-enyl]-chromen-2-one

Conditions
ConditionsYield
With sodium hydroxide In water at 20℃;93%
warfarin
81-81-2

warfarin

2-chloro-benzaldehyde
89-98-5

2-chloro-benzaldehyde

4-hydroxy-3-[5-(2-chloro-phenyl)-3-oxo-1-phenyl-pent-4-enyl]-chromen-2-one
1189759-37-2

4-hydroxy-3-[5-(2-chloro-phenyl)-3-oxo-1-phenyl-pent-4-enyl]-chromen-2-one

Conditions
ConditionsYield
With sodium hydroxide In water at 20℃;93%
warfarin
81-81-2

warfarin

4-nitrobenzaldehdye
555-16-8

4-nitrobenzaldehdye

4-hydroxy-3-[5-(4-nitro-phenyl)-3-oxo-1-phenyl-pent-4-enyl]-chromen-2-one
1189759-40-7

4-hydroxy-3-[5-(4-nitro-phenyl)-3-oxo-1-phenyl-pent-4-enyl]-chromen-2-one

Conditions
ConditionsYield
With sodium hydroxide In water at 20℃;93%
warfarin
81-81-2

warfarin

3-fluoro-3-(1-phenyl-3-oxobutyl)-2H-benzopyran-2,4-dione
910618-41-6

3-fluoro-3-(1-phenyl-3-oxobutyl)-2H-benzopyran-2,4-dione

Conditions
ConditionsYield
With N-fluorobis<(trifluoromethyl)sulfonyl>imide In chloroform; water at 35℃; for 0.25h;92%
poly(ethylene glycol), MW=2000, activated to carboxylic groups by succinic anhydride

poly(ethylene glycol), MW=2000, activated to carboxylic groups by succinic anhydride

warfarin
81-81-2

warfarin

A

warfarin conjugated with poly(ethylene glycol), MW=2000

warfarin conjugated with poly(ethylene glycol), MW=2000

B

1,3-Dicyclohexylurea
2387-23-7

1,3-Dicyclohexylurea

Conditions
ConditionsYield
With dmap; dicyclohexyl-carbodiimide In dichloromethane at 20℃; for 5h;A 85%
B n/a
furfural
98-01-1

furfural

warfarin
81-81-2

warfarin

4-hydroxy-3-(5-furan-2-yl-3-oxo-1-phenyl-pent-4-enyl)-chromen-2-one
1253372-65-4

4-hydroxy-3-(5-furan-2-yl-3-oxo-1-phenyl-pent-4-enyl)-chromen-2-one

Conditions
ConditionsYield
With sodium hydroxide In water at 20℃;85%
warfarin
81-81-2

warfarin

benzaldehyde
100-52-7

benzaldehyde

4-hydroxy-3-(3-oxo-1,5-diphenyl-pent-4-enyl)-chromen-2-one
1189759-35-0

4-hydroxy-3-(3-oxo-1,5-diphenyl-pent-4-enyl)-chromen-2-one

Conditions
ConditionsYield
With sodium hydroxide In water at 20℃;85%
warfarin
81-81-2

warfarin

4-methoxy-benzaldehyde
123-11-5

4-methoxy-benzaldehyde

4-hydroxy-3-[5-(4-methoxy-phenyl)-3-oxo-1-phenyl-pent-4-enyl]-chromen-2-one
1189759-38-3

4-hydroxy-3-[5-(4-methoxy-phenyl)-3-oxo-1-phenyl-pent-4-enyl]-chromen-2-one

Conditions
ConditionsYield
With sodium hydroxide In water at 20℃;85%
warfarin
81-81-2

warfarin

potassium warfarin
2610-86-8

potassium warfarin

Conditions
ConditionsYield
With pyrographite; potassium hydroxide In water; isopropyl alcohol at 75℃; for 8h; pH=7.8 - 8; Product distribution / selectivity; Inert atmosphere;81%
warfarin
81-81-2

warfarin

Warfarin-oxim

Warfarin-oxim

Conditions
ConditionsYield
With pyridine; sodium hydroxide; hydroxylamine hydrochloride In ethanol 1) 12 h, 2) reflux, 6 h;77%
warfarin
81-81-2

warfarin

vanadium(IV) fluoride
10049-16-8

vanadium(IV) fluoride

difluorovanadium(IV)di(4-oxo-3-(oxo-1-phenylbutyl)2H-1-benzopyran-2-one)

difluorovanadium(IV)di(4-oxo-3-(oxo-1-phenylbutyl)2H-1-benzopyran-2-one)

Conditions
ConditionsYield
In methanol methanolic soln. of VF4 added to methanolic soln. of C19H16O4 dropwise with stirring, mixt. had pH 3, refluxed for 2 h, kept overnight with stirring at room temp.; solvent removed on a rotary apparatus under reduced pressure; recrystn. (MeOH/n-hexane, 1/1); elem. anal., detd. by thermal anal.;77%
warfarin
81-81-2

warfarin

1-oxyl-4-carboxyl-2,2,6,6-tetramethylpiperidine
37149-18-1

1-oxyl-4-carboxyl-2,2,6,6-tetramethylpiperidine

2-oxo-3-[(RS)-3-oxo-1-phenylbutyl]-2H-chromen-4-yl 2,2,6,6-tetramethylpiperidine-1-oxyl-4-carboxylate

2-oxo-3-[(RS)-3-oxo-1-phenylbutyl]-2H-chromen-4-yl 2,2,6,6-tetramethylpiperidine-1-oxyl-4-carboxylate

Conditions
ConditionsYield
With dmap; dicyclohexyl-carbodiimide In dichloromethane; N,N-dimethyl-formamide at 0 - 20℃; for 26h; Inert atmosphere;75%
warfarin
81-81-2

warfarin

acetic anhydride
108-24-7

acetic anhydride

4-acetoxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one
5979-00-0

4-acetoxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one

Conditions
ConditionsYield
for 1h; Heating;71.4%
warfarin
81-81-2

warfarin

benzaldehyde
100-52-7

benzaldehyde

methylamine
74-89-5

methylamine

[3',4':5,6]pyrano[3,2-c]pyridine-6(7H)-one

[3',4':5,6]pyrano[3,2-c]pyridine-6(7H)-one

Conditions
ConditionsYield
In ethanol; water Heating; stereoselective reaction;68%
warfarin
81-81-2

warfarin

Benzyl bromoacetate
5437-45-6

Benzyl bromoacetate

C28H24O6

C28H24O6

Conditions
ConditionsYield
In acetone at 45℃; for 48h;65%
warfarin
81-81-2

warfarin

trifluoromethylsulfonic anhydride
358-23-6

trifluoromethylsulfonic anhydride

trifluoro-methanesulfonic acid 2-oxo-3-(3-oxo-1-phenyl-butyl)-2H-chromen-4-yl ester
929551-51-9

trifluoro-methanesulfonic acid 2-oxo-3-(3-oxo-1-phenyl-butyl)-2H-chromen-4-yl ester

Conditions
ConditionsYield
With triethylamine In chloroform at -5 - 25℃;62%
warfarin
81-81-2

warfarin

Trimethylboroxine
823-96-1

Trimethylboroxine

C20H18O4

C20H18O4

Conditions
ConditionsYield
With pentamethylcyclopentadienyl(benzene)cobalt(III) hexafluorophosphate; potassium carbonate; silver carbonate In 2-methyltetrahydrofuran at 60℃; for 16h; Inert atmosphere; Sealed tube;56%
methanol
67-56-1

methanol

warfarin
81-81-2

warfarin

2-methoxy-2-methyl-4-phenyl-3,4-dihydropyrano[3,2-c]chromen-5(2H)-one
518-20-7, 54288-87-8, 54288-88-9, 64753-99-7, 64754-00-3, 64754-01-4, 65207-43-4, 94902-10-0

2-methoxy-2-methyl-4-phenyl-3,4-dihydropyrano[3,2-c]chromen-5(2H)-one

2-methoxy-2-methyl-4-phenyl-3,4-dihydro-2H-pyrano[3,2-c]chromen-5-one

2-methoxy-2-methyl-4-phenyl-3,4-dihydro-2H-pyrano[3,2-c]chromen-5-one

Conditions
ConditionsYield
With hydrogenchloride for 23h; Reflux;A 53%
B 9%
warfarin
81-81-2

warfarin

benzyl bromide
100-39-0

benzyl bromide

C26H22O4

C26H22O4

Conditions
ConditionsYield
With potassium carbonate In acetone at 25℃; for 24h;38%
warfarin
81-81-2

warfarin

4'-Hydroxywarfarin
24579-14-4

4'-Hydroxywarfarin

Conditions
ConditionsYield
With culture of Cunninghamella bainieri In water for 144h; Product distribution; Ph7 phosphate buffer; metabolism of warfarin to 4'-hydroxywarfarin using the fungus Cunninghamella bainiery, possible mechanism of aromatic hydroxylation, primary isotope effect; inhibition of hydroxylation by CO;2 mg

81-81-2Relevant articles and documents

Ionic liquids: Efficient media for the lipase-catalyzed Michael addition

Fan, Yunchang,Cai, Dongxu,Wang, Xin,Yang, Lei

, (2018)

Recently, ionic liquids (ILs) have been regarded as ideal media for non-aqueous bio-catalysis. In this work, the synthesis of warfarin by the lipase-catalyzed Michael addition in IL media and the parameters that affected the warfarin yield were investigated. Experimental results demonstrated that the chemical structures of the ILs were a major factor for influencing the warfarin yield. The ILs containing the NTf2– anion were suitable reaction media due to the high chemical stability of this anion. The incorporation of the hydroxyl group on the IL cation significantly improved the lipase activity due to the H2O-mimicking property of this group. The lipase activity decreased by increasing the alkyl chain length on the IL cation due to the non-polar domain formation of the IL cation at the active site entrance of lipase. The ILs and lipase could be reused no less than five times without reduction in the warfarin yield.

Hypervalent Iodine(III)-Mediated Tosyloxylation of 4-Hydroxycoumarins

Xu, Bowen,Gao, Yiping,Han, Jianwei,Xing, Zejing,Zhao, Sihan,Zhang, Ziyang,Ren, Runlin,Wang, Limin

, p. 10136 - 10144 (2019)

An efficient approach was developed for synthesis of 3-tosyloxy-4-hydroxycoumarins under mild conditions by using Koser's reagents. The reaction tolerated various functional groups, and the products served as useful aromatic building blocks. Additionally, a plausible mechanism via iodonium ylide was proposed, and the oral anticoagulant Warfarin was synthesized in good yield.

Primary Amine Catalyzed Activation of Carbonyl Compounds: A Study on Reaction Pathways and Reactive Intermediates by Mass Spectrometry

Bencivenni, Giorgio,Calcaterra, Andrea,Ciogli, Alessia,Iazzetti, Antonia,Mazzoccanti, Giulia,Righi, Paolo,Villani, Claudio

supporting information, (2021/12/01)

The field of organocatalysis is expanding at a fast pace. Its growth is sustained by major stimuli, such as the effort toward an understanding of the mechanisms of reaction and catalytic processes in general, the elucidation of basic properties leading to stereocontrol and the search for broad applicability and scalability of the synthetic methodology. This paper reports a thorough study based on ESI-MS spectrometry of amino-organocatalyzed model reactions under different experimental conditions. Off-line reaction monitoring of mixtures containing different catalytic systems, by ESI-MSn showed the presence of several putative intermediate species, either in their protonated or sodiated forms. In addition, enantioselective chromatography of crude reactions provides the stereochemical outcome of asymmetric reactions. The bulk of the data collected offers a clue of the intricate pathways occurring in solution for the studied reactions.

Enantioselective Michael Addition Reaction Catalysed by Enantiopure Binuclear Nickel(II) Close-Ended Helicates

Arunachalam, Rajendran,Chinnaraja, Eswaran,Natarajan, Ramalingam,Samanta, Krishanu,Subramanian, Palani S.

, (2020/02/04)

The enantiopure Ni(II) helicates [Ni2L1RR.Cl2] (1), [Ni2L1SS.Cl2] (1′), [Ni2L2RR.Cl2] (2), [Ni2L2SS.Cl2] (2′) were synthesized by one-pot self-assembly technique from R-(+)- or S-(?)-1,1′-binaphthyl-2,2′-diamine, with 4-methyl-2,6-diformyl phenol or 4-tert-butyl-2,6-diformyl phenol and nickel salts. This binuclear double stranded Ni(II) helicates were characterized by ESI-MS, IR and single crystal X-ray structure wherever applicable. The extensive chiroptical studies suggest that the complexes are enantiopure in nature. The chirality transfer from ligand L1RR & L2RR to Ni(II) metal centre produced ΔΔ geometrical chirality, while their enantiomeric counterpart L1SS & L2SS produced ΛΛ chirality in their respective complexes.These enantiopure helicates were applied as catalysts in asymmetric Michael addition of 1,3-dicarbonyl compounds with β-nitrostyrene to produce nitroalkanes in good yield (96–98%) and ee (78–94%). (Figure presented.).

First aromatic amine organocatalysed activation of α,β-unsaturated ketones

Sonsona, Isaac G.,Marqués-López, Eugenia,Gimeno, M. Concepción,Herrera, Raquel P.

, p. 12233 - 12240 (2019/08/12)

This work provides an unprecedented example of a chiral aromatic amine used to activate α,β-unsaturated ketones in asymmetric aminocatalysis. Chiral aromatic diamine VII has been efficiently employed, as a proof of concept, in the Michael addition reaction between benzylideneacetones (1a-f) and coumarins (2a-d). The reaction gives rise to warfarin derivatives 3 with promising results using this family of catalysts for the first time. The additional studies performed supported the bifunctional mode of activation of the chiral catalyst VII and the covalent nature of the interactions between the catalyst VII and benzylideneacetones 1.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 81-81-2